TNDM241220C26000
- 3.90
- 0.000.00%
Tandem Diabetes Care Newsroom
Tandem Diabetes Care Analyst Ratings
Citi Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Cuts Target Price to $50
TD Cowen Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Cuts Target Price to $40
Tandem Diabetes Care Poised for Growth: Expansion Into Type 2 Diabetes and Strategic Integration Drive Buy Rating
Tandem Diabetes Care Raised to Overweight From Equal-Weight by Morgan Stanley
Tandem Diabetes Care Analyst Ratings
Morgan Stanley Upgrades Tandem Diabetes Care(TNDM.US) to Buy Rating, Maintains Target Price $45
Leerink Partners Keeps Their Buy Rating on Tandem Diabetes Care (TNDM)
Morgan Stanley Maintains Tandem Diabetes Care(TNDM.US) With Hold Rating, Maintains Target Price $45
Analysts Have Conflicting Sentiments on These Healthcare Companies: Waters (WAT), Pharvaris (PHVS) and Tandem Diabetes Care (TNDM)
Barclays Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Raises Target Price to $60
A Quick Look at Today's Ratings for Tandem Diabetes Care(TNDM.US), With a Forecast Between $40 to $75
Tandem Diabetes Care Is Maintained at Buy by Canaccord Genuity
Baird Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $37
Tandem Diabetes Care Analyst Ratings
A Quick Look at Today's Ratings for Tandem Diabetes Care(TNDM.US), With a Forecast Between $37 to $65
RBC Capital Remains a Buy on Tandem Diabetes Care (TNDM)
Bernstein Initiates Tandem Diabetes Care(TNDM.US) With Buy Rating, Announces Target Price $42
Stifel Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $60
Tandem Diabetes Care: Hold Rating Reiterated Amidst Market Challenges and Slow Product Uptake